---
title: "FDA panel approves expanded use of peptides in compounding pharmacies, raising concerns about prescription surge in billion-dollar industry."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293802908.md"
description: "The committee approved expanding the utilization of peptides in lightly regulated compounding pharmacies, which are now part of a multibillion-dollar industry."
datetime: "2026-07-24T22:24:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293802908.md)
  - [en](https://longbridge.com/en/news/293802908.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293802908.md)
generator: "portal-rs"
---

# FDA panel approves expanded use of peptides in compounding pharmacies, raising concerns about prescription surge in billion-dollar industry.

The committee approved expanding the utilization of peptides in lightly regulated compounding pharmacies, which are now part of a multibillion-dollar industry.

### Related Stocks

- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [Major Investor Makes Bold New Move on Seaport Therapeutics Stock](https://longbridge.com/en/news/285144653.md)
- [CMS To Offer Wegovy To Eligible Medicare Patients At $50 Monthly Copay Starting July 2026](https://longbridge.com/en/news/285583247.md)
- [Dyne Therapeutics To Submit BLA To FDA For Z- Rostudirsen](https://longbridge.com/en/news/287734064.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**